321 related articles for article (PubMed ID: 37446316)
21. Alterations in Sod2-Induced Oxidative Stress Affect Endocrine Cancer Progression.
Ashtekar A; Huk D; Magner A; La Perle KMD; Boucai L; Kirschner LS
J Clin Endocrinol Metab; 2018 Nov; 103(11):4135-4145. PubMed ID: 30165401
[TBL] [Abstract][Full Text] [Related]
22. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.
Melo M; da Rocha AG; Vinagre J; Batista R; Peixoto J; Tavares C; Celestino R; Almeida A; Salgado C; Eloy C; Castro P; Prazeres H; Lima J; Amaro T; Lobo C; Martins MJ; Moura M; Cavaco B; Leite V; Cameselle-Teijeiro JM; Carrilho F; Carvalheiro M; Máximo V; Sobrinho-Simões M; Soares P
J Clin Endocrinol Metab; 2014 May; 99(5):E754-65. PubMed ID: 24476079
[TBL] [Abstract][Full Text] [Related]
23. Differentiated thyroid carcinoma: An update.
Houten PV; Netea-Maier RT; Smit JW
Best Pract Res Clin Endocrinol Metab; 2023 Jan; 37(1):101687. PubMed ID: 36002346
[TBL] [Abstract][Full Text] [Related]
24. [Differentiated thyroid cancer--peculiar morphological and clinical forms].
Dănilă R; Andriescu L; Dăscălescu C; Lefter LP; Popovici R; Găluşcă B; Vulpoi C; Ungureanu C; Mogoş V; Dragomir C
Rev Med Chir Soc Med Nat Iasi; 2005; 109(4):746-52. PubMed ID: 16610171
[TBL] [Abstract][Full Text] [Related]
25. Thyroid nodules and differentiated thyroid cancer.
Bauer AJ
Endocr Dev; 2014; 26():183-201. PubMed ID: 25231453
[TBL] [Abstract][Full Text] [Related]
26. Risk of recurrence in a homogeneously managed pT3-differentiated thyroid carcinoma population.
Chereau N; Dauzier E; Godiris-Petit G; Noullet S; Brocheriou I; Leenhardt L; Buffet C; Menegaux F
Langenbecks Arch Surg; 2018 May; 403(3):325-332. PubMed ID: 29445865
[TBL] [Abstract][Full Text] [Related]
27. FOXE1 association with differentiated thyroid cancer and its progression.
Penna-Martinez M; Epp F; Kahles H; Ramos-Lopez E; Hinsch N; Hansmann ML; Selkinski I; Grünwald F; Holzer K; Bechstein WO; Zeuzem S; Vorländer C; Badenhoop K
Thyroid; 2014 May; 24(5):845-51. PubMed ID: 24325646
[TBL] [Abstract][Full Text] [Related]
28. Poorly differentiated carcinoma of the thyroid: an aggressive type of tumour arising from thyroid follicular epithelium.
Sakamoto A
Curr Top Pathol; 1997; 91():45-50. PubMed ID: 9018915
[No Abstract] [Full Text] [Related]
29. Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons.
Takami H; Ito Y; Okamoto T; Yoshida A
World J Surg; 2011 Jan; 35(1):111-21. PubMed ID: 21042913
[TBL] [Abstract][Full Text] [Related]
30. Single Point Mutations in Pediatric Differentiated Thyroid Cancer.
Alzahrani AS; Murugan AK; Qasem E; Alswailem M; Al-Hindi H; Shi Y
Thyroid; 2017 Feb; 27(2):189-196. PubMed ID: 27824297
[TBL] [Abstract][Full Text] [Related]
31. Radiation-Induced Differentiated Thyroid Cancer Is Associated with Improved Overall Survival but Not Thyroid Cancer-Specific Mortality or Disease-Free Survival.
White MG; Cipriani NA; Abdulrasool L; Kaplan S; Aschebrook-Kilfoy B; Angelos P; Kaplan EL; Grogan RH; Onel K
Thyroid; 2016 Aug; 26(8):1053-60. PubMed ID: 27279587
[TBL] [Abstract][Full Text] [Related]
32. Time to Separate Persistent From Recurrent Differentiated Thyroid Cancer: Different Conditions With Different Outcomes.
Sapuppo G; Tavarelli M; Belfiore A; Vigneri R; Pellegriti G
J Clin Endocrinol Metab; 2019 Feb; 104(2):258-265. PubMed ID: 30165559
[TBL] [Abstract][Full Text] [Related]
33. NONOPERATIVE MANAGEMENT OF DIFFERENTIATED THYROID CANCER IN CALIFORNIA: A POPULATION-LEVEL ANALYSIS OF 29,978 PATIENTS.
Kuo EJ; Wu JX; Li N; Zanocco KA; Yeh MW; Livhits MJ
Endocr Pract; 2017 Oct; 23(10):1262-1269. PubMed ID: 28816539
[TBL] [Abstract][Full Text] [Related]
34. Oncologic outcomes in patients with 1-cm to 4-cm differentiated thyroid carcinoma according to extent of thyroidectomy.
Choi JB; Lee SG; Kim MJ; Kim TH; Ban EJ; Lee CR; Lee J; Kang SW; Jeong JJ; Nam KH; Chung WY; Park CS
Head Neck; 2019 Jan; 41(1):56-63. PubMed ID: 30536465
[TBL] [Abstract][Full Text] [Related]
35. [Recovery rate in differentiated thyroid cancer. Experiences of one of the Hungarian clinical centers].
Szujó S; Bajnok L; Bódis B; Nemes O; Rucz K; Mezősi E
Orv Hetil; 2018 Jun; 159(22):878-884. PubMed ID: 29806478
[TBL] [Abstract][Full Text] [Related]
36. A population-based analysis of survival factors in differentiated and medullary thyroid carcinoma.
Bhattacharyya N
Otolaryngol Head Neck Surg; 2003 Jan; 128(1):115-23. PubMed ID: 12574769
[TBL] [Abstract][Full Text] [Related]
37. New therapeutic advances in the management of progressive thyroid cancer.
Woyach JA; Shah MH
Endocr Relat Cancer; 2009 Sep; 16(3):715-31. PubMed ID: 19218279
[TBL] [Abstract][Full Text] [Related]
38. Surgery for Neck Recurrence of Differentiated Thyroid Cancer: Outcomes and Risk Factors.
Lamartina L; Borget I; Mirghani H; Al Ghuzlan A; Berdelou A; Bidault F; Deandreis D; Baudin E; Travagli JP; Schlumberger M; Hartl DM; Leboulleux S
J Clin Endocrinol Metab; 2017 Mar; 102(3):1020-1031. PubMed ID: 28359102
[TBL] [Abstract][Full Text] [Related]
39. Prognostic Scores for Predicting Recurrence in Patients with Differentiated Thyroid Cancer.
Somboonporn C
Asian Pac J Cancer Prev; 2016; 17(5):2369-74. PubMed ID: 27268599
[TBL] [Abstract][Full Text] [Related]
40. [Anatomo-pathology and histological prognosis of follicular thyroid carcinoma].
de Micco C
Ann Endocrinol (Paris); 1997; 58(3):172-82. PubMed ID: 9239238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
